Table 1.
Concomitant medications of clinical interest
| Ibrutinib, n = 135 | Chlorambucil, n = 132 | |
|---|---|---|
| Antithrombotics, n (%) | 99 (73) | 71 (54) |
| Antiplatelets | 82 (61) | 67 (51) |
| Anticoagulants | 49 (36) | 13 (10) |
| Antihypertensives, n (%) | 98 (73) | 80 (61) |
| Agents acting on the renin-angiotensin system | 76 (56) | 55 (42) |
| β-Blocking agents | 62 (46) | 45 (34) |
| Calcium channel blockers | 49 (36) | 15 (11) |
| Other* | 15 (11) | 6 (5) |
| Acid-related disorders, n (%) | 87 (64) | 54 (41) |
| H2-receptor antagonists | 23 (17) | 10 (8) |
| Proton pump inhibitors | 75 (56) | 47 (36) |
| Other† | 17 (13) | 3 (2) |
| Neutrophil growth factors, n (%) | 13 (10) | 16 (12) |
*
Excluding agents acting on the renin-angiotensin system, β-blocking agents, and calcium channel blockers.
†
Excluding proton pump inhibitors or H2-blockers.